FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384343875> ?p ?o ?g. }

• W4384343875 endingPage "e352" @default.
• W4384343875 startingPage "e347" @default.
• W4384343875 abstract "Background: Obesity is a major and growing public health concern. The associated cost for obesity and its related comorbidities is approximately 30% of US health care expenditures annually. As additional pharmacotherapeutic options join the market to combat obesity, it is important to understand the financial impact it may have on overall health care costs. This article explores the efficacy and pharmacoeconomics of incretin mimetics, semaglutide and tirzepatide, in the setting of obesity. Area of Uncertainty: The cost of incretin mimetics (semaglutide and tirzepatide) and its overall impact on obesity management within the health care arena is being explored. The cost comparison of these medications is to be determined; however, it may represent an added cost to the total US health care expenditures. Data Sources: A PubMed and Google Scholar search was conducted using various search terms (eg, semaglutide, tirzepatide, pharmacoeconomics, and obesity). Therapeutic Advances: Based on the data reviewed, both semaglutide and tirzepatide are effective medication options for obesity management. Obesity-related management expenditures exceed $173 billion for the US health care system annually. The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide was reported as $1845 and $985, respectively. More than 40% of adults (60 years or older) experience obesity. If 1%, 5%, or 10% of this population is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively. Tirzepatide is not yet approved in the United States for obesity and its financial impact remains to be seen. Conclusions: Obesity is associated with burdensome health complications and costs. Semaglutide and tirzepatide are effective drug options for the management of obesity. The cost of these medications will no doubt present a challenge to the total health care expenditures, although the cost–benefit ratio may ultimately be favorable." @default.
• W4384343875 created "2023-07-15" @default.
• W4384343875 creator A5006514089 @default.
• W4384343875 creator A5034869825 @default.
• W4384343875 creator A5076404171 @default.
• W4384343875 date "2023-07-01" @default.
• W4384343875 modified "2023-09-30" @default.
• W4384343875 title "Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity" @default.
• W4384343875 cites W1852003516 @default.
• W4384343875 cites W1977220675 @default.
• W4384343875 cites W1978454776 @default.
• W4384343875 cites W2069724389 @default.
• W4384343875 cites W2107832644 @default.
• W4384343875 cites W2135610518 @default.
• W4384343875 cites W2147648477 @default.
• W4384343875 cites W2609075277 @default.
• W4384343875 cites W2746751342 @default.
• W4384343875 cites W2769181855 @default.
• W4384343875 cites W2995759968 @default.
• W4384343875 cites W3011482816 @default.
• W4384343875 cites W3127371223 @default.
• W4384343875 cites W3137152050 @default.
• W4384343875 cites W4214607566 @default.
• W4384343875 cites W4214685336 @default.
• W4384343875 cites W4281934192 @default.
• W4384343875 cites W4310940908 @default.
• W4384343875 cites W4311206282 @default.
• W4384343875 cites W4311448281 @default.
• W4384343875 cites W4323925813 @default.
• W4384343875 doi "https://doi.org/10.1097/mjt.0000000000001643" @default.
• W4384343875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37449929" @default.
• W4384343875 hasPublicationYear "2023" @default.
• W4384343875 type Work @default.
• W4384343875 citedByCount "2" @default.
• W4384343875 countsByYear W43843438752023 @default.
• W4384343875 crossrefType "journal-article" @default.
• W4384343875 hasAuthorship W4384343875A5006514089 @default.
• W4384343875 hasAuthorship W4384343875A5034869825 @default.
• W4384343875 hasAuthorship W4384343875A5076404171 @default.
• W4384343875 hasConcept C126322002 @default.
• W4384343875 hasConcept C134018914 @default.
• W4384343875 hasConcept C160735492 @default.
• W4384343875 hasConcept C162324750 @default.
• W4384343875 hasConcept C177713679 @default.
• W4384343875 hasConcept C2776738588 @default.
• W4384343875 hasConcept C2777180221 @default.
• W4384343875 hasConcept C2781308992 @default.
• W4384343875 hasConcept C2908647359 @default.
• W4384343875 hasConcept C2909862629 @default.
• W4384343875 hasConcept C50522688 @default.
• W4384343875 hasConcept C511355011 @default.
• W4384343875 hasConcept C555293320 @default.
• W4384343875 hasConcept C71924100 @default.
• W4384343875 hasConcept C99454951 @default.
• W4384343875 hasConceptScore W4384343875C126322002 @default.
• W4384343875 hasConceptScore W4384343875C134018914 @default.
• W4384343875 hasConceptScore W4384343875C160735492 @default.
• W4384343875 hasConceptScore W4384343875C162324750 @default.
• W4384343875 hasConceptScore W4384343875C177713679 @default.
• W4384343875 hasConceptScore W4384343875C2776738588 @default.
• W4384343875 hasConceptScore W4384343875C2777180221 @default.
• W4384343875 hasConceptScore W4384343875C2781308992 @default.
• W4384343875 hasConceptScore W4384343875C2908647359 @default.
• W4384343875 hasConceptScore W4384343875C2909862629 @default.
• W4384343875 hasConceptScore W4384343875C50522688 @default.
• W4384343875 hasConceptScore W4384343875C511355011 @default.
• W4384343875 hasConceptScore W4384343875C555293320 @default.
• W4384343875 hasConceptScore W4384343875C71924100 @default.
• W4384343875 hasConceptScore W4384343875C99454951 @default.
• W4384343875 hasIssue "4" @default.
• W4384343875 hasLocation W43843438751 @default.
• W4384343875 hasLocation W43843438752 @default.
• W4384343875 hasOpenAccess W4384343875 @default.
• W4384343875 hasPrimaryLocation W43843438751 @default.
• W4384343875 hasRelatedWork W2036143472 @default.
• W4384343875 hasRelatedWork W2089401470 @default.
• W4384343875 hasRelatedWork W2098459940 @default.
• W4384343875 hasRelatedWork W2166875150 @default.
• W4384343875 hasRelatedWork W2411416190 @default.
• W4384343875 hasRelatedWork W4213302520 @default.
• W4384343875 hasRelatedWork W4313486492 @default.
• W4384343875 hasRelatedWork W4377715503 @default.
• W4384343875 hasRelatedWork W4383420526 @default.
• W4384343875 hasRelatedWork W4384343875 @default.
• W4384343875 hasVolume "30" @default.
• W4384343875 isParatext "false" @default.
• W4384343875 isRetracted "false" @default.
• W4384343875 workType "article" @default.